Citi Starts CRISPR Therapeutics (CRSP) at Neutral

November 15, 2016 7:41 AM EST
Get Alerts CRSP Hot Sheet
Price: $21.93 +2.00%

Rating Summary:
    3 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 22 | New: 54
Trade CRSP Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Citi initiated coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Neutral rating and a price target of $19.00.

For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.

Shares of CRISPR Therapeutics closed at $17.60 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

New Coverage

Related Entities

Citi

Add Your Comment